Proteasome Inhibitors Market – By Drug Type, By Application, By Distribution Channel - Global Forecast 2025 – 2034

Proteasome Inhibitors Market Size

The global proteasome inhibitors market size was valued at around USD 2.7 billion in 2024 and is estimated to grow at 8.7% CAGR from 2025 to 2034. Proteasome inhibitors are a type of cytotoxic medications that demonstrate anticancer capability by permanently inhibiting the chymotrypsin-like enzymatic activity of the proteasome, which is involved in cellular breakdown of proteins. The current applications of proteasome inhibitors are in oncology, for the treatment of mantle cell lymphoma and multiple myeloma. Various clinical trials are underway to expand its clinical applications.
 

The increasing hematologic cancer incidence, including multiple myeloma and mantle cell lymphoma, is driving the market growth. For instance, according to the Global Cancer Observatory, there were 187,952 new cases of multiple myeloma and 121,388 fatalities in 2022, across the world. Proteasome inhibitors manage and treat these conditions by disturbing cancer cell survival and proliferation, resulting in a heightened market demand.
 

Additionally, growing research and development investments by drug manufacturers to create new proteasome inhibitors with broader clinical uses, potential for combination treatment, and greater efficacy are supporting market growth. For instance, in April 2023, Avacta Group, a life sciences company engaged in targeted oncology, announced the submission of pre-clinical data of its AVA3996, a CISION proteasome inhibitor, to the American Association for Cancer Research (AACR). Such novel drug development initiatives by various potential market players is expected to drive the demand for market over the forecast period.
 

Proteasome Inhibitors Market Trends

• The patent expiry of Velcade (bortezomib) in 2022 has led to the increasing adoption of novel proteasome inhibitors such as Kyprolis (carfilzomib), Ninlaro (Ixazomib), and some generic version of bortezomib. These novel drugs offer improved risk management, enhanced efficiency, and better affordability compared to conventional first-generation treatments like Velcade.
   
• Further, regulatory agencies like the European Medicines Agency (EMA), the National Medical Products Administration (NMPA), and the U.S. FDA are offering their valuable assistance to drug companies active in the market of proteasome inhibitors through funding support, orphan drug designations, and accelerated approvals owing to the critical demand for new drugs against aggressive and uncommon cancers like multiple myelomas and mantle cell lymphoma.
   
• Growing focus towards ready-to-use oncology products are enabling healthcare providers to reduce the time involved in compounding preparations, that is typically required during therapeutic administration.
   
• Additionally, easy availability of funding for the development of new proteasome inhibitors are enabling new opportunities for treating patients with cancer, inflammation and autoimmune diseases. For instance, in September 2022, QLi5 announced that the company received USD 10.9 million as part of their series A financing round for the advancement of their pipeline of highly differentiated proteasome inhibitors.
   

Proteasome Inhibitors Market Analysis

Based on drug type, the market is segmented into branded and generic. The global market for proteasome inhibitors was valued at USD 2.5 billion in 2023. The branded segment dominated the market with the largest revenue share of 64.8% in 2024.
 

• The increasing incidence of multiple myeloma is a significant driver of the branded segment, as branded therapies such as Kyprolis (carfilzomib) is finding increasingly adoption in the treatment of multiple myeloma. Further, according to the National Institutes of Health (NIH), the mortality and incidence of multiple myeloma are estimated to increase by 79% and 71% respectively during 2021-2025.
   
• Moreover, branded therapies such as Kyprolis (carfilzomib) and Velcade (bortezomib) have shown enhanced efficacy compared to some currently available myeloma therapies, translating to better patient's outcomes. Its high target affinity facilitates inhibition of proteasome activity, consequently resulting in effective disease management.
   
• Additionally, the increasing adoption of combination therapies such as KD (Kyprolis and dexamethasone) and KRD (Kyprolis, lenalidomide, and dexamethasone) due to their extraordinary efficiency is further driving segment growth.

Based on application, the proteasome inhibitors market is bifurcated into multiple myeloma and mantle cell lymphoma. The multiple myeloma segment dominated the market with the largest revenue share of 92.5% in 2024.
 

• The increasing incidence of multiple myelomas is propelling the market for targeted therapies like proteasome inhibitors. For example, according to the National Institutes of Health (NIH), multiple myeloma accounts for approximately 10% of all hematological malignancies and 1% of all cancers. The high volume of new cases and the increasing awareness regarding early detection and treatment options is driving segment growth.
   
• Further, advancements in research have resulted in the development of novel proteasome inhibitors under pipeline such as MLN9708 and NPI-0052. These novel therapeutics are expected to improve the treatment outcomes and enhance the therapeutic armamentarium of patients suffering from multiple myeloma.
   
• In addition, growing usage of combination therapies using proteasome inhibitors, chemotherapy, and immune checkpoint inhibitors is propelling the segment growth. The combination therapies significantly improve survival rate and therapeutic efficacy in cancer patients.
   

Based on distribution channel, the proteasome inhibitors market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment dominated the market with the largest revenue of USD 1.9 billion in 2024.
 

• Proteasome inhibitors such as Kyprolis (carfilzomib) and Velcade (bortezomib) require subcutaneous or intravenous administration, that are usually administered across acute care facilities such as hospitals. Hospitals have substantial resources to monitor patient responses and manage side effects during such complex therapies. This increases the procurement of medications from hospital pharmacies.
   
• Moreover, various major private and public insurance providers offer better reimbursement rates for hospital pharmacy purchases as compared to retail or outpatient pharmacies.

North America: The U.S. proteasome inhibitors market revenue is expected to increase considerably from USD 1.1 billion in 2024 to USD 2.5 billion by 2034.
 

• The high volume of new multiple myeloma cases in the U.S. due to various factors such as growing awareness, increasing cancer screening initiatives, aging population, and advancements in diagnostic technologies is driving market growth in the region. For instance, according to the American Cancer Society, approximately 36,110 new cases and 12,030 fatalities are expected to occur in 2025 due to multiple myeloma in the U.S.
   
• Also, the presence of numerous biotechnology and pharmaceutical companies, such as Amgen, Takeda Pharmaceutical Company, and Fresenius Kabi, which are involved in the development and sale of new proteasome inhibitors is propelling regional market growth.
   

Europe: The proteasome inhibitors market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The growing incidence of mantle cell lymphoma in the UK due to factors such as aging population, genetic expressions, and unhealthy lifestyle is driving the demand for novel treatments such as proteasome inhibitors. For instance, according to Lymphoma Action, approximately 600 new cases of mantle cell lymphoma are diagnosed in the UK every year, highlighting the need for effective novel treatments.
   
• In addition, the presence of various dedicated oncology centers and research organizations such as the University College London, Christie NHS Foundation Trust, and The Royal Marsden supports the development of novel proteasome inhibitor treatments, facilitating the market growth in the region.
   

Asia Pacific: Japan proteasome inhibitors market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan has one of the highest volumes of geriatric population in the world, resulting in a higher risk and prevalence of multiple myeloma. For instance, according to the World Economic Forum, more than 10% of the Japanese population is aged 80 years and older, highlighting the need for effective novel treatment options.
   
• According to the May 2023 study published by National Centers for Biotechnology Information, each year, approximately 4,000 deaths are recorded due to multiple myeloma in Japan.
   
• Additionally, the presence of Takeda Pharmaceutical Company, the developer of Velcade (bortezomib) and Ninlaro (Ixazomib), in Japan ensures easy availability of novel proteasome inhibitors-based treatments, which is one of the major driving factors of the market growth in the country.
   

Middle East and Africa: The proteasome inhibitors market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Heavy investments in healthcare infrastructure through the establishment of dedicated hematology and oncology centers in organizations such as National Guard Health Affairs, King Faisal Specialist Hospital & Research Centre, and King Fahad Medical City is driving the development and clinical research of various novel proteasome inhibitors.
   
• Additionally, the increasing incidence of multiple myeloma in the country is driving the demand for innovative treatment options including the proteasome inhibitors. For instance, according to the Global Cancer Observatory, approximately 295 new cases and 229 fatalities related to multiple myeloma were reported in 2022 in Saudi Arabia.
   

Proteasome Inhibitors Market Share

The market is concentrated, featuring 2 pharmaceutical firms having approved products. The top players in this market include Takeda Pharmaceutical Company and Amgen accounting for approximately 100% of the market share. These players are investing in the development of advanced treatments to enhance treatment efficiency. Moreover, strategic partnerships with research institutions and healthcare providers are critical for integrating modern technologies and expanding distribution, which will enable the companies to address the surge in demand for treatment options. The market experiences a regulatory support and streamlined approval processes which further motivates to innovate and facilitates market entry. Additionally, emerging players such as Celgene Corporation and Fresenius Kabi are focussing on development of new treatments which aim to improve disease management. These innovations continue to promote market progression.
 

Proteasome Inhibitors Market Companies

Some of the eminent market participants operating in the proteasome inhibitors industry include:

• Amgen
• Amneal Pharmaceuticals
• Apotex
• Aurobindo Pharma
• Baxter International
• Bristol Myer Squibb
• Camber Pharmaceuticals
• Dr. Reddy's Laboratories
• Fresenius Kabi
• Gland Pharma
• Johnson & Johnson
• QLi5 Therapeutics
• Sagent Pharmaceuticals
• Selleck Chemicals
• Takeda Pharmaceutical Company
• Zydus
   
• Amgen is a major player in the market. The company’s Kyprolis (carfilzomib) drug has a significant market presence. Its strong and extensive biopharma research and development expertise is facilitating innovation in proteasome inhibitors, further strengthening its market position.
   
• Takeda Pharmaceutical Company is the developer of the first approved proteasome inhibitor treatment, Velcade (bortezomib), indicated for the treatment of mantle cell lymphoma and multiple myeloma. The company significantly invests in the expansion of its oncology pipeline. Ninlaro (Ixazomib) is another proteasome inhibitor in the company’s portfolio that is gaining significant market traction.
   
• Fresenius Kabi provides an extensive line of oncology products, including oncology generics such as Bortezomib for Injection. The company, through its KabiCare program, offers copay assistance, that helps in reducing the overall out-of-pocket costs for the therapy.
   

Proteasome Inhibitors Industry News:

• In September 2024, Amneal Pharmaceuticals and Shilpa Medicare received U.S. FDA approval for BORUZU, a ready-to-use intravenous (IV) bortezomib formulation. BORUZU is used in oncology and simplifies the preparation process during administration.
   
• In May 2022, Aurobindo Pharma received final approval from the U.S. FDA to manufacture and sell a Bortezomib-based anti-cancer injection, which is a generic version of Takeda Pharmaceuticals' Velcade.
   
• In February 2022, Baxter International received U.S. FDA approval for its Bortezomib Injection (Single-Dose Vial), which is used to treat adult patients with multiple myeloma and mantle cell lymphoma.
   

The proteasome inhibitors market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Branded
  • Velcade (bortezomib)
  • Kyprolis (carfilzomib)
  • Ninlaro (Ixazomib) 
• Generic

Market, By Application

• Multiple myeloma
• Mantle cell lymphoma

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America 
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE